The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
Nearly 50 years after the “war on cancer” was declared in the United States, precision medicine is changing the face of cancer research.
Al final de los 1800, un cirujano…